key: cord-0717487-tj85zvac
authors: Putman, Michael; Sattui, Sebastian E.; Sparks, Jeffrey A.; Liew, Jean W.; Grainger, Rebecca; Duarte‐García, Alí
title: Evidence in the Time of COVID‐19
date: 2021-03-28
journal: Arthritis Rheumatol
DOI: 10.1002/art.41745
sha: 7f63eb60ef9122ac744bf33c2f48540737f34c8e
doc_id: 717487
cord_uid: tj85zvac

We thank Tang et al. for their interest in our study and correspondence on an important clinical question. In May of 2020 when our literature search was last updated, we did not identify any case series, cohort studies, or randomized controlled trials (RCTs) that evaluated the role of hydroxychloroquine as prophylaxis for COVID‐19. Consequently, our analysis was unable to address this issue. The authors should be commended for their efforts to conduct an RCT during the early phases of the pandemic when there was widespread misinformation about antimalarials. We empathize with the difficulties they encountered, which highlight broader issues impacting the COVID‐19 research agenda.

We thank Tang et al. for their interest in our study and correspondence on an important clinical question. In May of 2020 when our literature search was last updated, we did not identify any case series, cohort studies, or randomized controlled trials (RCTs) that evaluated the role of hydroxychloroquine as prophylaxis for COVID-19. Consequently, our analysis was unable to address this issue. The authors should be commended for their efforts to conduct an RCT during the early phases of the pandemic when there was widespread misinformation about antimalarials. We empathize with the difficulties they encountered, which highlight broader issues impacting the COVID-19 research agenda.

As noted in our analysis, early observational studies frequently had a high risk of bias, which could be attributed to small sample sizes, inappropriate or inadequate comparator groups, and issues related to confounding by indication. Over-interpretation of the preliminary evidence led to offlabel hydroxychloroquine use months before the first randomized trial was finished. An "infodemic" began, (1) fueled by anecdotal reports of encouraging benefit and concerning harms. A seemingly contradictory situation arose, where enrollment slowed because of overconfidence in hydroxychloroquine's purported benefit and trials were paused or terminated in response to potential safety signals. The typical regulatory and logistic hurdles to initiating RCTs compounded delays, resulting in many RCTs beginning after COVID-19 peaks had passed. Perhaps most importantly, aside from notable exceptions like the RECOVERY trials (2), few large scale coordinated RCTs of HCQ were performed.

The importance of conducting large scale adequately powered RCTs -and the consequences of relying on sub-optimal evidence when they are absent -will be one of the enduring legacies of the COVID-19 pandemic (3, 4) . Performing such trials will require greater collaboration between centers and a regulatory environment that encourages their execution. It will also require investigators like Tang et al., who were willing to expend time and effort in this worthy endeavor.

The Lancet Infectious Diseases. The COVID-19 infodemic

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Azithromycin, RECOVERY, and the power of large, simple trials

The Magic of Randomization versus the Myth of Real-World Evidence